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Recently an association between cytomegalovirus (CMV)
replication after allogeneic hematopoietic cell trans-
plantation (HCT) and decreased risk of relapse was described
in a cohort of patients with acute myeloid leukemia (AML)
[Blood. 2011;118(5):1402]. We evaluated this proposed
protective effect of CMV replication in a larger cohort of
consecutive patients with AML (n¼761), as well as patients
with acute lymphoblastic leukemia (ALL) (n¼322), chronic
myelogenous leukemia (CML) (n¼646), and lymphoma
(n¼254) who received an allogeneic HCT at the FHCRC
between 1995 and 2005. All patients underwent weekly
surveillance for CMV replication with pp65-antigenemia
through day 100 after HCT. Antiviral therapy with ganciclovir
was initiated after any positive antigenemia. In multivariable
models, CMV antigenemia at any level was associated with
a decreased risk of morphologic relapse by day 100 among
patients with AML (adjusted HR 0.56, 95% CI 0.34-0.91, P ¼
.02), ALL (adjusted HR 0.21, 95% CI 0.05-1.00, P ¼ .05) and
lymphoma (adjusted HR 0.37, 95% CI 0.13-1.02, P ¼ .05) but
not CML (adjusted HR 0.72, 95% CI 0.2-2.3, P ¼ .58). Higher
levels of antigenemia (>10 positive cells, and >10 positive
cells for two consecutive weeks) were not associated with
incremental protection from relapse for any group. The effect
appeared to be independent of acute GvHD (grade 3-4) or
ganciclovir-related neutropenia (ANC< 500). The association
between early CMV reactivation and relapse protection in
patients with acute leukemia and lymphoma persisted at 1
year after HCT (adjusted HR 0.69, 95% CI 0.5-0.9, P¼ .006) but
was undetectable at 3 years. However, there was no differ-
ence in overall survival at either 100 days or 1 year after HCT
among patients with any level of CMV antigenemia
compared to patients with no CMV reactivation. In conclu-
sion, these data demonstrate an association between CMV
reactivation and decreased risk of early relapse among AML,
ALL and lymphoma, but not CML, patients after allogeneic
HCT. Further laboratory investigations are warranted to
deﬁne the mechanisms of this protection.105
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Background: Idiopathic pneumonia syndrome (IPS) is
a severe respiratory complication that can occur in 2-15% of
allogeneic hematopoietic cell transplant (HCT) recipients. IPS
is clinically characterized by widespread alveolar injury, not
caused by infection, cardiac dysfunction, acute renal failure,
or ﬂuid overload. Although current understanding of IPF
pathogenesis is limited, human and animal models of IPS and
acute lung injury suggest that inﬂammatory and ﬁbrotic
pathways may be involved. We investigated whether single
nucleotide polymorphisms (SNPs) in and near candidate
genes previously found to be associated with acute lung
injury may inﬂuence the risk for developing IPS.
Methods: We conducted a genetic association study using
clinical data and DNA from 67 IPS and 783 control patients.
IPS was deﬁned by chart review according to American
Thoracic Society Guidelines. All SNPs within the candidate
gene and +/-50kb identiﬁed from the 1000 Genome Project
were either genotyped using the Affymetrix GeneChip
Genome-Wide SNP 5.0 (n¼470) or the Illumina 1M Quad
(n¼380), or imputed using previously published methods.
All SNPs were analyzed in additive, dominant, and recessive
multivariate genetic models and the Bonferroni method was
used to adjust for multiple comparisons. Association
between the AGT SNPs and plasma AGT levels was evaluated
in an independent cohort of 378 allogeneic HCT patients.
Results: A total of 1277 SNPs (31 genotyped in both cohorts,
293 genotyped in one cohort and imputed in another, 953
imputed in both cohorts) in 8 candidate genes (ACE, AGT,
SP-B, RANTES, DARC, MCP-1, TNFa and TNFR II) were evalu-
ated. Six SNPs in AGT (rs3827749, rs3789666, rs3789667,
rs2478545, rs2478544 and rs1078499, ﬁve out six are
imputed) met the signiﬁcance threshold and were associated
with an increase in IPS risk in a recessive genetic model
(hazard ratio range 3.58 e 4.71, P-value range .001 e .0004).
In an independent cohort, all 6 SNPs were found to be
signiﬁcantly associated with lower plasma AGT levels in the
recessive genetic model (mean AGT levels: homozygous
recessive 17.8 e 22.4 ng/mL, heterozygous and homozygous
wild type 27.3 ng/mL, P-value range .002 e .00001).
Conclusions: These results suggest that renin-angiotensin
system may be involved in the pathogenesis of IPS after
allogeneic HCT.
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Background: Human rhinovirus (HRV) is the most common
respiratory viral infection following hematopoietic cell
transplantation (HCT); the day 100 cumulative incidence is
22%. HRV can progress to lower respiratory tract (LRT)
infection. The clinical signiﬁcance of HRV RNA in LRT secre-
tions is unclear.We analyzed the outcome and risk factors for
mortality in HCT recipients with HRV RNA detection in the
LRT, comparing survival of patients with LRT infection due to
HRV and other respiratory viruses.
Methods: A retrospective cohort of 87 HCT recipients trans-
planted between 6/1993e4/2012 at FHCRC had HRV RNA
detected in LRT by bronchoalveolar lavage (BAL) or biopsy
using culture (N¼13) and/or real time RT-PCR (N¼80); all
patients had LRT symptoms and/or pulmonary inﬁltrates.
Factors associatedwith overallmortalitywere analyzed using
Cox proportional hazards models. Comparison cohorts with
parainﬂuenza virus (PIV, N¼55), RSV (N¼111), or inﬂuenza A
(FLU, N¼41) LRT infection were included in the analyses.
Samples from a separate control cohort of 21 asymptomatic
HCT patientswithout radiographic abnormalities undergoing
research BAL between day 35e50 were also studied.
Results: Median age of the 87 patients was 48.5 years (range
1e71); median time to HRV LRT detection after HCT was 81
days (range0e3596). Viral/fungal/bacterial copathogenswere
present in 48%of patients. Probability of 180-day survival after
HRV detection was 59%. Multivariable analysis showed that
oxygen use at diagnosis (HR 2.6, P¼ .04), steroid use 1mg/kg
prior to diagnosis (HR 5.5, P¼ .002), and bonemarrowas stem
cell source (HR 2.3, P ¼ .05) were associated with poor
outcome. The presence of copathogens did not signiﬁcantly
affect mortality (HR 1.1, P¼ .71) (Figure 1). Survival at day 180
inpatientswithHRVLRT infection and LRT infection causedby
other respiratoryviruseswas similar (Figure1); after adjusting
for stem cell source and baseline steroid and oxygen use, no
statistically signiﬁcant difference in mortality between HRV
and any of the other viruses was found (adjusted HR versus
HRV without copathogens: HRV with copathogens, HR 0.96;
PIV, HR 1.05; RSV, HR 0.93; FLU, HR 1.47). HRVwas detected in
only one asymptomatic control patient (5%).
Conclusions: HCT recipients who underwent BAL or biopsy
for lung diseasewith HRV RNAdetection had a highmortality
even in the absence of copathogens. Outcome was not
statistically signiﬁcantly different from patients with RSV,
inﬂuenza or PIV LRT disease. These results suggest that HRV is
a pathogen that is associated with severe pulmonary disease,
and is associated with mortality rates comparable to well-
recognized viral pathogens. Additional studies are ongoing to
deﬁne the role of viral load and HRV genotypes on outcome.
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Introduction: The impaired B and T cell immunity of HCT
recipients increases their susceptibility to infectious diseases
like herpes zoster (HZ). However, the licensed live-attenu-
ated HZ vaccine is not appropriate for highly immunocom-
promised individuals. Recombinant subunit vaccines are an
alternative to live-attenuated vaccines. VZV glycoprotein E
(gE) is an attractive candidate antigen. We report on the
safety and immunogenicity of two formulations of a VZV
subunit vaccine candidate administered on a 2- or 3-dose
schedule to autologous HCT recipients.
Methods: This was a Phase I/II, randomized, placebo-
controlled, multicenter study. Adults with multiple
myeloma, non-Hodgkin B or T cell lymphoma, Hodgkin
lymphoma, or acute myeloid leukemia who had undergone
autologous HCT 50e70 days earlier were randomized 1:1:1:1
to receive 3 doses (at months 0, 1, and 3) of 50 mg gE
combined with the adjuvant AS01B (50 mg MPL/QS21) or
AS01E (25 mg MPL/QS21), 1 dose of saline followed by 2 doses
of gE/AS01B, or 3 doses of saline. Serum anti-gE antibody
concentrations were measured by ELISA and frequencies
of gE-speciﬁc CD4+ T cells expressing 2 activation
markers by intracellular cytokine staining up to month 15.
Solicited local and systemic adverse events (AEs) were
recorded up to 7 days after each immunization (graded 1e3).
Unsolicited AEs were reported from the ﬁrst immunization
up to 30 days after the ﬁnal immunization. Serious AEs
were reported throughout the study. (Clinicaltrials.gov,
NCT00920218).
Results: 120 subjects were vaccinated. gE-speciﬁc antibody
concentrations and activated CD4+ T cell frequencies were
higher with all gE/AS01 regimens than with saline at month
4 and persisted up to month 15 (all P < .0001). For gE/AS01B,
3 doses were more immunogenic than 2, but 3 doses of gE/
AS01B were not signiﬁcantly more immunogenic than 3
doses of gE/AS01E. The most common solicited AEs were
pain, fatigue, andmyalgia. Overall, grade 3 AEs were reported
in 10.3%e36.7% of vaccine and6.7% of saline recipients. One
non-fatal SAE was considered possibly related to vaccination
in the gE/AS01B 2-dose group. Eleven subjects died, of which
seven died from malignancy recurrence. Four cases of HZ
were conﬁrmed during the study, two each in the gE/AS01E3-
dose and saline groups.
